Articolul precedent |
Articolul urmator |
410 15 |
Ultima descărcare din IBN: 2023-11-01 19:49 |
SM ISO690:2012 BOTNARI-GUȚU, Mihaela, IVANOV, Elena, CODREANU, Igor. Endometrioza și calitatea vieții. Abordări terapeutice. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 580. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 580-580 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Endometriosis is one of the most current women's health problems. It is known that this disease ranks 3rd in the structure of gynecological diseases, it is found in 5-10% of women, 35-50% of women with infertility and 70-80% of women with chronic pelvic pain. Objective of the study. Comparative evaluation of two treatment schemes, used in the management of endometriosis symptoms and their impact in restoring quality of life. Material and Methods. A prospective nonrandomized case-control clinical trial was performed that included 104 gynecopathic patients. The study group included 43 patients with endometriosis who received contraceptive treatment with dienogest and estradiol valerate administered on a continuous scheme. The control group included 37 patients with endometriosis who were treated with dienogest 2 mg. Results. The study evaluated the statistically true similar efficacy of both treatment schemes in the management of chronic pelvic pain (21.6%vs16.6%, OR 1.17, p=0.8), dyspareunia (5.9% vs 4.9%, OR 1.40, p=0.5),dysmenorrhea (13.8% vs 11.8%, OR 1.18, p=0.7). Dienogest was associated with significant improvement in symptoms and onset of amenorrhea at week 24. DNG+E2V was associated with the improvement of symptoms and the onset of amenorrhea in week 8 of treatment.The study shows that more common side effects are found in the group of patients who received Dienogest compared to DNG + E2V, the most common being spotting,vaginal dryness ,hot flashes,intermenstrual hemorrhages . Conclusion. The study evaluated the statistically true similar efficacy of both treatment schemes in the management of chronic pelvic pain, dyspareunia, dysmenorrhea. The scheme with DNG+E2V was more effective in reducing side effects. The treatment with DNG+E2V was more cost effective, more accessible. |
||||||
Cuvinte-cheie endometriosis quality of life pelvic pain dysmenorrhea, endometrioză, Calitatea vieţii, Dismenoree, durere pelvină cronică |
||||||
|